… protein called the M5 muscarinic acetylcholine receptor. The presence of this unique receptor presents a unique … we will use a multidisciplinary approach to understand how the M5 receptor interacts with the “parkinsonian state.” … Diagnosis/Treatment of Parkinson’s disease:  The successful completion of these studies will provide the preclinical …

… mediating the endothelial dysfunction is not well understood. Here we leveraged the Organs-on-Chips technology to … mitochondrial impairment, neuroinflammation, and compromised barrier function. This model may enable research … synucleinopathies and serve as a testing platform for target identification and validation of novel therapeutics. …

… awareness around the importance of brain health and to one day, see a world where degenerative brain diseases no … connection, research is piecing together the puzzle of how to best care for your brain, how to prevent disease and, … to Boost Better Brain Health,” to amplify and empower the community on their journey toward caring for our brains.   …

… public policy and advocacy, on September 9 – 10 in Washington, D.C. for the 2019 Parkinson’s Policy Forum. The event … Todd Sherer, PhD. “The Parkinson’s Policy Forum brings the community together to advocate for government policies that support …

…                Gait and balance disorders are the primary motor disability in advanced Parkinson’s disease (PD). These disorders arise in part due to dysfunction of the lateral mesencephalus [part of the … may be effective but that we lack standardized tools for finding the ideal target. Study Design: In this project, we …

… Study Rationale:   The complexity of Parkinson’s disease (PD) has contributed to the poor success rate in drug development. At Neumora we … 1) translational biomarker development to support target engagement, as well as, for downstream lysosomal …